Favorable survival for older adults treated with Axi-cel and Tisa-cel CD19 CAR-T therapy for relapsed/refractory DLBCL: a U.S. multicenter comparative analysis.
Older adults benefit from advanced cell therapies just as younger patients do, challenging age-based treatment barriers.
The abstract reports our results support the practice that age alone should not be a barrier to CAR-T consultation or therapy. This PubMed record was retained because it is relevant to treatment innovation.
What the study was
- Study design
- Cohort study
- Sample size
- 65
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Transplantation and cellular therapy
Why it surfaced
Cohort study relevant to Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma), Novel therapeutics: immunotherapy, CAR-T, targeted therapy, Aging, longevity, and population health; scored conservatively from the PubMed abstract.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.